NF-κB gene signatures and p53 mutations in head and neck squamous cell carcinoma

Clinical Cancer Research

Volumn 13, Issue 19, 2007, Pages 5663-5664

  Ferris, Robert L ^a   Grandis, Jennifer R ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CHEMOKINE RECEPTOR CCR7; CYCLIN D1; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; INTERLEUKIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN P53; SCATTER FACTOR; STEROID;

ANTINEOPLASTIC ACTIVITY; CARCINOGENESIS; CELL INTERACTION; DNA DAMAGE; EDITORIAL; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; NASOPHARYNX CARCINOMA; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; BIOLOGICAL MODEL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HEAD AND NECK TUMOR; INFLAMMATION; METABOLISM; MULTIGENE FAMILY; MUTATION; NOTE; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

CARCINOMA, SQUAMOUS CELL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HEAD AND NECK NEOPLASMS; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; MULTIGENE FAMILY; MUTATION; NF-KAPPA B; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 35348838471     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1544     Document Type: Editorial

References (20)

1. Leeman RJ, Lui VW, Grandis JR. STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther 2006;6:231-41.
2. Lee TL, Yang XP, Yan B, et al. A novel NF-kB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status. Clin Cancer Res 2007;13:5680-91.
3. Quon H, Liu FF, Cummings BJ. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck 2001;23:147-59.
4. Lingen MW, Emami B, Clark JI. New therapeutic strategies for the treatment and prevention of head and neck cancer. Expert Opin Investig Drugs 2000;9:2855-72.
5. Elledge RM, Clark GM, Fuqua SA, Yu YY, Allred DC. p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res 1994;54:3752-7.
6. Linkov F, Lisovich A, Yurkovetsky Z, et al. Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol Biomarkers Prev 2007;16:102-7.
7. Allen GW, Saba C, Armstrong EA, et al. Insulin-like growthf actor-I receptor signaling blockade combined withr adiation. Cancer Res 2007;67:1155-62.
8. Hiscott J, Kwon H, Genin P. Hostile takeovers: viral appropriation of the NF-κB pathway. J Clin Invest 2001;107:143-51.
9. Mishra A, Bharti AC, Varghese P, Saluja D, Das BC. Differential expression and activation of NF-κB family proteins during oral carcinogenesis: role of high risk human papillomavirus infection. Int J Cancer 2006;119:2840-50.
10. Tang G, Minemoto Y, Dibling B, et al. Inhibition of JNK activation through NF-κB target genes. Nature 2001;414:313-7.
11. Fausch SC, Fahey LM, Da Silva DM, Kast WM. Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation. J Immunol 2005;174:7172-8.
12. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients withadv anced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003;21:2237-46.
13. Mburu YK, Wang J, Wood MA, Walker WH, Ferris RL. CCR7 mediates inflammation-associated tumor progression. Immunol Res 2006;36:61-72.
14. Campbell KJ, Perkins ND. Regulation of NF-κB function. Biochem Soc Symp 2006;73:165-80.
15. Chen X, Shen B, Xia L, et al. Activation of nuclear factor κB in radioresistance of TP53-inactive human keratinocytes. Cancer Res 2002;62:1213-21.
16. Loercher A, Lee TL, Ricker JL, et al. Nuclear factor-κB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res 2004;64:6511-23.
17. Liu L, Backlund LM, Nilsson BR, et al. Clinical significance of EGFR amplification and the aberrant EGFR-vIII transcript in conventionally treated astrocytic gliomas. J Mol Med 2005;83:917-26.
18. Van Waes C, Chang AA, Lebowitz PF, et al. Inhibition of nuclear factor-κB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005;63:1400-12.
19. Campbell KJ, Witty JM, Rocha S, Perkins ND. Cisplatin mimics ARF tumor suppressor regulation of RelA (p65) nuclear factor-κB transactivation. Cancer Res 2006;66:929-35.
20. Yan B, Yang X, Lee TL, et al. Genome-wide identification of novel expression signatures reveal distinct patterns and prevalence of binding motifs for p53, NF-κB, and other signal transcription factors in head and neck squamous cell carcinoma. Genome Biol 2007;8:R78.